Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8dc1442e8263a086103a8b2a6b9753f9 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24143 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-10034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00117 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001182 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00119 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001193 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001194 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001102 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001149 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001152 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2019-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b8d0a4f44310c20cc483dd235aea9a4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96e001d7e8c4fd04d1a9ae1425f58074 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44db86111c69e4dfeb3b109aebdc9e63 |
publicationDate |
2022-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2022000997-A1 |
titleOfInvention |
Therapy for Treating Cancer with an Intratumoral or Intravenous Administration of a Recombinant MVA Encoding 4-1BBL (CD137L) and/or CD40L |
abstract |
The invention relates to a composition and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The composition comprises a recombinant MVA encoding a Tumor Associated Antigen (“TAA”) as well as 4-1BBL and/or CD40L and can be administered to a subject in any suitable manner, including by intravenous and/or intratumoral administration. |
priorityDate |
2019-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |